CHOLESTEROL METABOLISM IN THE SMITH-LEMLI-OPITZ SYNDROME
Smith-Lemli-OPITZ 综合征中的胆固醇代谢
基本信息
- 批准号:2403400
- 负责人:
- 金额:$ 17.54万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1995
- 资助国家:美国
- 起止时间:1995-05-01 至 1998-04-30
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
Background; The Smith-Lemli-Opitz Syndrome (frequency ca 1:20,000) is a
major public health problem which is described by a constellation of severe
birth defects, including profound mental retardation and severe failure to
thrive heretofore diagnosed only from its characteristic facies and limb
and organ defects. We have recently reported, for the first time, a major
biochemical defect in the syndrome. In 28 children plasma cholesterol
levels (4 to 132 mg/dl) are below the fifth percentile for age matched
controls while concentrations (6 to 61 mg/dl) of the cholesterol precursor
7-dehydrocholesterol (cholest-5,7-dien-3beta-ol) are elevated 2500 to 6000-
fold above normal. Although not detected in controls, 7-dehydrocholesterol
is also found in high concentrations in all tissues as well as in cultured
fibroblasts. Abnormally low plasma cholesterol concentrations combined
with high levels of 7-dehydrocholesterol demonstrate major block in
cholesterol biosynthesis at the step in which the C-7,8 double bond of 7-
dehydrocholesterol is reduced to form cholesterol. This may be sufficient
to cause cholesterol deprivation in the embryo and fetus and prevent its
proper development while the incorporation of 7-dehydrocholesterol in cells
is likely to interfere with proper membrane function. We have also
affected a prenatal diagnosis in two women by detecting elevated 7-
dehydrocholesterol in amniotic fluid. An isotope incorporation assay in
fibroblasts suggest that a test for carriers might be possible.
Planned Studies: Our goals are to further define the biochemical defect in
the syndrome by measurements of tissue lipids, by carrying out in vitro
measurements of appropriate enzymes in the cholesterol biosynthetic pathway
(3beta-hydroxy-delta 5.7-steroid delta7--reductase and HMG-CoA reductase)
in affected, carrier and control fibroblasts cultured under various
conditions and to examine cellular function and membrane properties under
conditions of reduced C-7 reductase activity. An animal model of the
disease is being developed and has already been used to plan and test
treatment strategies and to further study the biochemistry of the disease.
Four children have been placed on controlled high cholesterol diets
(replacement therapy). As a results, their plasma cholesterol levels
appeared to increase and they seem to progress a little more rapidly.
Finally a collaborative effort is being planned to purify the C-7 reductase
enzyme, sequence it and clone the cDNA. Eventually, it is hoped that an
efficient test for carriers will be developed.
背景; Smith-Lemli-Opitz综合征(频率Ca 1:20,000)是一个
主要的公共卫生问题,这是通过严重的星座来描述的
出生缺陷,包括严重的智力低下和严重失败
迄今为止,thrive仅从其特征相和肢体诊断出来
和器官缺陷。 我们最近首次报道了一个专业
综合征的生化缺陷。 在28个孩子中血浆胆固醇
水平(4至132 mg/dl)低于年龄匹配的第五百分点
对照,而胆固醇前体的浓度(6至61 mg/dL)
7-脱氢胆固醇(Cholest-5,7-Dien-3beta-Ol)的升高2500至6000-
折叠高于正常。 尽管未在对照中检测到7-脱氢胆固醇
在所有组织以及培养的所有组织中也有高浓度
成纤维细胞。 异常低血浆胆固醇浓度合并
高水平的7-脱氢胆固醇在
胆固醇生物合成在c-7,8双键为7-的步骤中
脱氢胆固醇还原为形成胆固醇。 这可能足够
在胚胎和胎儿中引起胆固醇剥夺并防止其
正确发育,而在细胞中掺入7-脱氢胆固醇
可能会干扰适当的膜功能。 我们也有
通过检测升高的7--
羊水中的脱氢胆固醇。 同位素合并测定
成纤维细胞表明可能可以进行载体测试。
计划研究:我们的目标是进一步定义生化缺陷
通过测量组织脂质的综合征,通过体外进行
测量胆固醇生物合成途径中适当酶的测量
(3beta-Hydroxy-delta 5.7-Syteroid Delta7-还原酶和HMG-COA还原酶)
在受影响的,载体和控制的成纤维细胞中培养的成纤维细胞
条件并检查细胞功能和膜特性
C-7还原酶活性降低的条件。 一个动物模型
疾病正在开发并已用于计划和测试
治疗策略并进一步研究该疾病的生物化学。
四个孩子被放置在受控的高胆固醇饮食上
(替代疗法)。 结果,它们的血浆胆固醇水平
似乎增加了,它们似乎进步更快。
最后,正在计划净化C-7还原酶
酶,测序它并克隆cDNA。 最终,希望
将开发对载体的有效测试。
项目成果
期刊论文数量(22)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
7-Dehydrocholesterol down-regulates cholesterol biosynthesis in cultured Smith-Lemli-Opitz syndrome skin fibroblasts.
- DOI:
- 发表时间:1998-03
- 期刊:
- 影响因子:6.5
- 作者:M. Honda;G. Tint;Akira Honda;Lien B. Nguyen;Thomas S. Chen;Sarah Shefer
- 通讯作者:M. Honda;G. Tint;Akira Honda;Lien B. Nguyen;Thomas S. Chen;Sarah Shefer
Defective conversion of 7-dehydrocholesterol to cholesterol in cultured skin fibroblasts from Smith-Lemli-Opitz syndrome homozygotes.
- DOI:
- 发表时间:1995-07
- 期刊:
- 影响因子:6.5
- 作者:Akira Honda;G. Tint;G. Salen;A. Batta;Thomas S. Chen;S. Shefer
- 通讯作者:Akira Honda;G. Tint;G. Salen;A. Batta;Thomas S. Chen;S. Shefer
Competitive inhibition of hepatic sterol 27-hydroxylase by sitosterol: decreased activity in sitosterolemia.
谷甾醇对肝甾醇 27-羟化酶的竞争性抑制:谷甾醇血症时活性降低。
- DOI:
- 发表时间:1998
- 期刊:
- 影响因子:0
- 作者:Nguyen,LB;Shefer,S;Salen,G;Tint,SG;Batta,AK
- 通讯作者:Batta,AK
Accurate detection of Smith-Lemli-Opitz syndrome carriers by measurement of the rate of reduction of the ergosterol C-7 double bond in cultured skin fibroblasts.
通过测量培养的皮肤成纤维细胞中麦角甾醇C-7双键的减少率,准确检测Smith-Lemli-Opitz综合征携带者。
- DOI:10.1023/a:1005401317306
- 发表时间:1998
- 期刊:
- 影响因子:4.2
- 作者:Honda,M;Tint,GS;Shefer,S;Honda,A;Batta,AK;Xu,G;Chen,TS;Salen,G
- 通讯作者:Salen,G
Regulation of the last two enzymatic reactions in cholesterol biosynthesis in rats: effects of BM 15.766, cholesterol, cholic acid, lovastatin, and their combinations.
大鼠胆固醇生物合成中最后两个酶促反应的调节:BM 15.766、胆固醇、胆酸、洛伐他汀及其组合的影响。
- DOI:10.1002/hep.510240223
- 发表时间:1996
- 期刊:
- 影响因子:0
- 作者:Honda,A;Shefer,S;Salen,G;Xu,G;Batta,AK;Tint,GS;Honda,M;Chen,TC;Holick,MF
- 通讯作者:Holick,MF
共 15 条
- 1
- 2
- 3
G STEPHEN TINT的其他基金
CHOLESTEROL METABOLISM IN THE SMITH-LEMLI-OPITZ SYNDROME
Smith-Lemli-OPITZ 综合征中的胆固醇代谢
- 批准号:22047772204777
- 财政年份:1995
- 资助金额:$ 17.54万$ 17.54万
- 项目类别:
CHOLESTEROL METABOLISM IN THE SMITH-LEMLI-OPITZ SYNDROME
Smith-Lemli-OPITZ 综合征中的胆固醇代谢
- 批准号:22047782204778
- 财政年份:1995
- 资助金额:$ 17.54万$ 17.54万
- 项目类别:
相似国自然基金
妊娠糖尿病母体羊水和母乳低聚糖组成对后代发育及远期健康的影响及其机制研究
- 批准号:
- 批准年份:2021
- 资助金额:55 万元
- 项目类别:面上项目
羊水间充质干细胞增殖新基因Abca4及其下游调控分子在优化干细胞体外扩增与治疗方面应用的研究
- 批准号:
- 批准年份:2021
- 资助金额:30 万元
- 项目类别:青年科学基金项目
羊水间充质干细胞增殖新基因Abca4及其下游调控分子在优化干细胞体外扩增与治疗方面应用的研究
- 批准号:32100640
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
妊娠糖尿病母体羊水和母乳低聚糖组成对后代发育及远期健康的影响及其机制研究
- 批准号:82173500
- 批准年份:2021
- 资助金额:55.00 万元
- 项目类别:面上项目
未足月胎膜早破患者羊水来源的外泌体对羊膜上皮细胞的功能调控及作用机制研究
- 批准号:82001585
- 批准年份:2020
- 资助金额:24 万元
- 项目类别:青年科学基金项目
相似海外基金
Engineering of Polymeric Particles for Fetal Therapy
用于胎儿治疗的聚合物颗粒工程
- 批准号:1058628210586282
- 财政年份:2023
- 资助金额:$ 17.54万$ 17.54万
- 项目类别:
Prenatal Exposure to Endocrine Disrupting Chemicals and Risk of Testicular Cancer (DISRUPT)
产前接触内分泌干扰化学物质与睾丸癌 (DISRUPT) 的风险
- 批准号:1037398510373985
- 财政年份:2020
- 资助金额:$ 17.54万$ 17.54万
- 项目类别:
Wadsworth Center's Human Health and Exposure Analysis Resource (WC-HHEAR)
沃兹沃斯中心的人类健康和暴露分析资源 (WC-HHEAR)
- 批准号:1087665710876657
- 财政年份:2015
- 资助金额:$ 17.54万$ 17.54万
- 项目类别:
CHEMISTRY SERVICES FOR THE NATIONAL TOXICOLOGY PROGRAM, Sub 1
国家毒理学计划子 1 的化学服务
- 批准号:94435529443552
- 财政年份:2014
- 资助金额:$ 17.54万$ 17.54万
- 项目类别: